be971158-ffec-4142-afc3-4ea3164fa86c
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 63
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.550
- G2M_CHECKPOINT+0.530
- E2F_TARGETS+0.500
- MYC_TARGETS_V1+0.490
- WNT_BETA_CATENIN_SIGNALING+0.320
- MITOTIC_SPINDLE+0.310
- OXIDATIVE_PHOSPHORYLATION+0.290
- ESTROGEN_RESPONSE_LATE+0.250
- MTORC1_SIGNALING+0.250
- SPERMATOGENESIS+0.240
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- ALLOGRAFT_REJECTION-0.380
- COMPLEMENT-0.360
- INFLAMMATORY_RESPONSE-0.350
- COAGULATION-0.330
- MYOGENESIS-0.330
- INTERFERON_GAMMA_RESPONSE-0.320
- TNFA_SIGNALING_VIA_NFKB-0.320
- ANGIOGENESIS-0.300
- KRAS_SIGNALING_UP-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-04155 | — | cohortSQ2 | 0.903 |
| 2 | TCGA-22-5477-01A-01R-1635-07 | — | cohortSQ2 | 0.886 |
| 3 | TCGA-70-6723-01A-11R-1820-07 | — | cohortSQ2 | 0.883 |
| 4 | TCGA-94-A5I4-01A-11R-A26W-07 | — | cohortSQ2 | 0.878 |
| 5 | 5d2d4263-d17d-424f-9c82-bf665306d71f | — | — | 0.877 |
| 6 | TCGA-MF-A522-01A-11R-A262-07 | — | cohortSQ2 | 0.874 |
| 7 | TCGA-33-4538-01A-01R-1201-07 | — | cohortSQ2 | 0.874 |
| 8 | e235012b-4b29-478a-abad-6a70cd949cfa | — | — | 0.872 |
| 9 | C3N-01411 | — | cohortSQ2 | 0.868 |
| 10 | E3A67B7B-7427-4C11-912B-166451072767 | — | — | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.550 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.320 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.310 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.170 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.140 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.120 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.080 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.060 | Idelalisib | — uncovered |